Polyethyleneimine-Modified Laminarin Nanoparticles as Vaccine Adjuvants: Mechanistic Advances in Antigen Delivery and Immune Enhancement

Study Background and Research Question

Modern vaccine development increasingly focuses on nanotechnology to improve antigen delivery, enhance immune responses, and reduce toxicity. Traditional adjuvants such as aluminum salts, while effective in stimulating antibody production, often fall short in eliciting robust cellular immunity or enabling efficient cytosolic delivery of antigens. Natural polysaccharides—biocompatible, low-toxicity polymers—have gained attention as adjuvant candidates due to their immunomodulatory properties and ease of functional modification. Laminarin, a β-glucan polysaccharide, exhibits promising biological activities, but its utility as a nanovaccine carrier is limited by suboptimal cellular uptake and antigen presentation efficiency. The reference study addresses whether surface modification of laminarin nanoparticles with polyethyleneimine (PEI) can overcome these hurdles, improve antigen loading, and drive stronger immune responses when used as an adjuvant for the model antigen ovalbumin (OVA).

Key Innovation from the Reference Study

The central innovation lies in the functionalization of laminarin nanoparticles with PEI, creating a cationic surface that facilitates strong electrostatic interactions with negatively charged protein antigens such as OVA. This modification yields CLam/OVA nanoparticles with an optimal mean diameter (~380 nm), uniform size distribution, and stable colloidal properties. Critically, the positive surface charge significantly enhances internalization by bone marrow-derived dendritic cells (BMDCs), promoting antigen uptake and initiating the cascade of cellular events required for effective vaccine-induced immunity. Unlike conventional adjuvants, the PEI-modified laminarin system specifically supports lysosomal escape, a key step for cross-presentation of antigens and activation of cytotoxic T lymphocytes.

Methods and Experimental Design Insights

The authors synthesized cationic laminarin (CLam) by covalently attaching PEI to laminarin chains, then complexed this with OVA to create CLam/OVA nanoparticles. Physicochemical properties—including particle size, zeta potential, and colloidal stability—were characterized using dynamic light scattering and electron microscopy. In vitro, BMDCs were incubated with CLam/OVA to assess uptake, maturation (CD80, CD86 expression), and antigen cross-presentation capacity. Lysosomal escape and intracellular trafficking were investigated using fluorescence microscopy, leveraging probes such as Lyso-Tracker Red DND-99 for tracking lysosomal compartments. Signaling pathway activation was probed by monitoring toll-like receptor (TLR2/4), cytokine receptor, and chemokine-mediated responses. In vivo, mice immunized with CLam/OVA were compared to those receiving OVA alone or with aluminum adjuvant, evaluating antibody titers, T cell responses, and cytokine secretion.

Core Findings and Why They Matter

Key findings from the reference study include:

• Enhanced Cellular Uptake: The cationic surface of CLam/OVA particles significantly increased BMDC internalization compared to unmodified nanoparticles and aluminum adjuvant formulations.
• Lysosomal Escape and Cross-Presentation: The nanoparticles promoted efficient lysosomal escape of OVA, as visualized by the redistribution of fluorescent antigen from Lyso-Tracker Red-labeled compartments into the cytosol. This process improved cross-presentation efficiency, a critical requirement for CD8⁺ T cell activation.
• BMDC Maturation and Signaling: CLam/OVA induced upregulation of maturation markers (CD80, CD86) and activated TLR2 and TLR4 signaling pathways, driving robust cytokine production and chemokine-mediated recruitment of immune cells.
• Superior Humoral and Cellular Immunity: Mice immunized with CLam/OVA generated higher OVA-specific antibody titers and stronger cytotoxic T lymphocyte responses, including elevated IFN-γ secretion, than those immunized with aluminum adjuvant or OVA alone.

These results demonstrate the value of PEI-based surface modification in engineering nanovaccine platforms that address the dual challenges of antigen stability and efficient cytosolic delivery, thereby potentiating both humoral and cellular arms of adaptive immunity.

Protocol Parameters

• Nanoparticle preparation: Mix cationic laminarin (PEI-modified) with OVA under controlled pH and ionic strength to achieve ~380 nm particle size and stable zeta potential.
• BMDC uptake assays: Incubate BMDCs with CLam/OVA nanoparticles for 4–6 hours to assess internalization and maturation; use Lyso-Tracker Red DND-99 (50–75 nM) to visualize lysosomal compartments during uptake studies.
• In vivo immunization: Administer CLam/OVA nanoparticles via subcutaneous or intramuscular injection in mice, with booster doses as required; monitor immune responses at 7–28 days post-immunization.
• Antigen cross-presentation assessment: Use flow cytometry for CD8⁺ and CD4⁺ T cell activation markers and cytokine (IFN-γ) secretion following antigen recall assays.

These parameters are based on the approaches detailed in the reference study and may be further optimized depending on antigen and carrier system.

Comparison with Existing Internal Articles

The mechanistic advances in lysosomal escape and antigen cross-presentation described here align with recent insights from internal resources on lysosome labeling and tracking in live cells. For example, articles such as "Lyso-Tracker Red DND-99: Precision Lysosome Labeling in Live Cells" and "Lyso-Tracker Red: Advancing Lysosomal Imaging for Translational Impact" emphasize the importance of high-specificity fluorescent probes for studying intracellular acidic compartments and lysosomal dynamics. In the context of vaccine delivery, the ability to visualize antigen trafficking and lysosomal escape using Lyso-Tracker Red DND-99 is especially relevant, as it allows real-time monitoring of nanoparticle fate and antigen processing in live antigen-presenting cells.

Moreover, the cross-talk between lysosomal permeabilization and immune cell activation, as explored in "SGI-1027 and Everolimus Synergy: Lysosomal Permeabilization in RCC", further highlights the translational potential of live-cell lysosome tracking for both immunology and cancer research. These internal studies reinforce the value of precise lysosomal labeling in optimizing nanoparticle-based immunotherapies and provide workflow guidance for researchers adapting similar experimental designs.

Limitations and Transferability

Although the PEI-modified laminarin nanoparticle platform demonstrates clear improvements in antigen delivery and immune activation, several limitations warrant consideration. First, the use of OVA as a model antigen, while standard for proof-of-concept studies, may not fully predict efficacy or safety with clinically relevant antigens. Second, PEI modifications, while enhancing cellular uptake, can potentially increase cytotoxicity or alter biodistribution, necessitating careful dose optimization and toxicity assessment for translational applications. Third, the in vitro and murine in vivo models used in the reference study may not capture the full complexity of human immune responses or long-term safety outcomes. Finally, while the lysosomal escape mechanism is demonstrated, further studies are needed to detail the molecular pathways and potential off-target effects in different cell types.

Research Support Resources

To facilitate studies of nanoparticle uptake, lysosomal trafficking, and antigen cross-presentation, researchers may employ high-specificity lysosomal probes such as Lyso-Tracker Red (SKU B8814, APExBIO). Lyso-Tracker Red DND-99 is widely used for live-cell imaging of intracellular acidic compartments, enabling robust visualization and quantification of lysosomal integrity, morphology, and antigen release. Detailed protocols and troubleshooting strategies are discussed in internal resources such as "Lyso-Tracker Red DND-99: Precision Lysosome Labeling in Live Cells". For optimal results, Lyso-Tracker Red is typically applied at nanomolar concentrations to live cells, with careful attention to storage and handling as outlined in the product information.